Adaptive Biotechnologies Corp

For the period ended Mar 31, 2025. Filed May 1, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 1, 2025

ADPT$30.26+8.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Shareholders’ Equity

(in thousands, except share amounts)

Common Stock · Additional · Accumulated Other · Accumulated · Noncontrolling · Total
	Shares	Amount	Paid-In Capital	Comprehensive Gain (Loss)	Deficit	Interest	Shareholders’ Equity
Balance at December 31, 2023	145,082,271	$14	$1,452,502	$215	$(1,144,332)	$(121)	$308,278
Issuance of common stock for cash upon exercise of stock options	30,900	—	44	—	—	—	44
Vesting of restricted stock units, net	2,255,153	—	—	—	—	—	—
Share-based compensation expense	—	—	14,298	—	—	—	14,298
Other comprehensive loss	—	—	—	(321)	—	—	(321)
Net loss	—	—	—	—	(47,507)	(26)	(47,533)
Balance at March 31, 2024	147,368,324	$14	$1,466,844	$(106)	$(1,191,839)	$(147)	$274,766
Balance at December 31, 2024	147,773,744	$14	$1,506,353	$166	$(1,303,824)	$(224)	$202,485
Issuance of common stock for cash upon exercise of stock options	882,493	1	5,450	—	—	—	5,451
Vesting of restricted stock units and market-based restricted stock units	3,260,485	—	—	—	—	—	—
Share-based compensation expense	—	—	12,147	—	—	—	12,147
Other comprehensive loss	—	—	—	(32)	—	—	(32)
Net (loss) income	—	—	—	—	(29,852)	22	(29,830)
Balance at March 31, 2025	151,916,722	$15	$1,523,950	$134	$(1,333,676)	$(202)	$190,221

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.